St. Jude Medical Announces CE Mark Approval of OptiSense Pacing Lead

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced CE Mark approval of its new OptiSense™ lead, a first-of-its-kind pacing lead designed to offer more accurate sensing in the upper chamber of the heart (right atrium). The lead, which will be introduced at the Europace 2007 Meeting in Lisbon, Portugal, incorporates a new tip design that increases the device’s ability to detect and classify electrical signals in the atrium more accurately by avoiding picking up signals from the heart's lower chambers (ventricles). This improves the pacemaker’s response to sensed signals and the accuracy of device diagnostic reports.